🔗 Share this article

As the US undertakes historic adjustments to its vaccine guidelines, a particular individual has surfaced somewhat surprisingly: Høeg, an American of Danish descent physician and public health researcher who initially gained attention by casting doubt on Covid vaccines throughout the global health crisis and has zeroed in on possible deaths after Covid immunization in her recent tenure at the Food and Drug Administration.

Proposed Overhauls to Pediatric Vaccine Schedule

Health officials planned to announce radical revisions to the pediatric vaccine schedule recently, aligning the US with Denmark’s immunization schedule, it is understood – a major change that would place the US out of alignment with a large portion of the international standard with insufficient data for public health gain. This reveal has been pushed back until the next year.

Instead of Vinay Prasad, Tracy Beth Høeg is scheduled to speak at the event. She was newly appointed temporary leader of the FDA’s CDER, the fifth person to head the office this calendar year.

A Shift at the Regulatory Body

The acting appointment might represent a closer partnership between the pharmaceutical and biologics divisions as Høeg and Prasad consolidate power at the FDA – and it signals a greater focus upon reevaluating previously authorized vaccines at the FDA.

Dr. Høeg has frequently advocated for ending certain childhood immunization guidelines in the US so as to align more in line with Denmark, a society with universal health coverage and a population about the size of Wisconsin’s.

So far statements, she has kept her attention on immunizations – typically the purview of Dr. Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of drug regulation.

Concerns Over Qualifications

The appointee has no apparent track record in medication creation, oversight or administrative roles, which has been standard for former leaders of the CBER. She has worked at the FDA as a top consultant to the FDA chief and the vaccine center since March.

“It seems she lacks to have the requisite experience” for leading the pharmaceutical oversight division, remarked Dr. Jonathan Howard. “She has not conducted a scientific study. She has no expertise in managing a sizeable institution. She is not an expert in industry regulation.”

Former heads of CBER would “understand laws and regulations and the science of pharmaceutical innovation”, said Dr. Janet Woodcock. “Frankly, she lacks the kind of background that prior appointees who led the center have had.”

This division has an vast range of responsibilities at the agency, the former commissioner emphasized.

“The public just focuses on the novel medication approvals, but the off-patent medication office approves thousands of generic medications. There’s a biosimilars division, non-prescription drug unit and other areas, and every single one have to be supervised,” she explained. “The area you overlook, that is the part that I always told people is going to come back to haunt you.”

There is also, a significant administrative aspect to the role, which supervises more than 5,000 personnel. “It’s a enormous leadership role, if you do it right,” Woodcock concluded.

Agency Reaction and Disputed Programs

When asked about concerns about Dr. Høeg's fitness for the role and whether this appointment signifies more teamwork among agency officials on immunizations, a press secretary stated that the “concerns stem from inaccurate presumptions”.

“This background is consistent with the responsibilities of her position,” the official stated, citing the time Høeg spent advising the FDA commissioner on “medication safety and approval science, including computerized risk analysis and vaccine surveillance”.

As acting director, Høeg inherits the commissioner’s controversial expedited review system, a contentious one-day drug-approval program that reportedly worried her predecessors. “By what process are these medications being chosen for this fast-track system? Who is making the calls?” Dr. Howard said. “There is a lot of confidentiality occurring at the regulatory body right now.”

Overall, he stated, “the agency appears to be shifting towards more relaxed regulations of most medications, aside from shots.”

Public History on Immunizations

Regarding vaccines, Dr. Høeg has a clearer, if problematic, past, Howard observe. She published a analysis using non-validated crowd-sourced reports to determine the rate of myocarditis after COVID-19 immunization. She consulted for the state of Florida top health official Joseph Ladapo, who reportedly have changed statistics to imply Covid vaccines are riskier than they are.

Included in her “policy goals” for the incoming federal leadership featured changing guidelines for new vaccines and ending “non-essential” vaccines, she stated post-election on a online show. At the FDA, Dr. Høeg has reportedly suggested barring teenage boys from receiving COVID-19 vaccinations.

“She is an all-around true believer who commences with her beliefs and tailors the evidence to fit the science in a highly deceptive, untruthful way,” Dr. Howard argued.

Taking Control and a “Campaign of Retribution”

Dr. Høeg became part of other contrarians, {like|